Regeneron Pharmaceuticals

REGN US Health Care Biotechnology
S&P 500 Nasdaq 100
$781.49
-1.48%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.06.
  • Comfortable interest cover: operating profit covers interest about 81.7 times.
  • Return on equity is moderate at 14.2%.
  • Net profit margin is strong at 31.4%.
  • Current assets comfortably cover current liabilities (current ratio 4.13).

!Watch-points

  • Return on capital employed is on the lower side at 9.6%.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreSafe zone
7.76

In Altman’s original study, companies in this range showed a low incidence of financial distress.

Piotroski F-ScoreModerate
4 / 7

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 7 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap$80.46B
Current Price$ 781.49
High / Low$ 859.34 / 541.00
Stock P/E19.343811
Book Value$ 299.16
Dividend Yield0.46%
ROCE9.58%
ROE14.21%
Debt to Equity0.06
Current Ratio4.13
P/B Ratio2.4722013
EPS$ 41.48
Debt$1.99B
PAT Margin31.41%
Cash PAT$5.05B
ICR81.69
Educational data only. Not a recommendation to buy, sell or hold any security.